Umer Raffat
Stock Analyst at Evercore ISI Group
(1.36)
# 3,354
Out of 4,749 analysts
20
Total ratings
52.94%
Success rate
-7.82%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $22.99 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $3.65 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $1.84 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $1.14 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $31.53 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $16.92 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical | Upgrades: Outperform | n/a | $17.73 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $5.99 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $10.30 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $38.10 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.56 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.40 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $1.42 | +3,280.28% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $285.42 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $4.55 | +954.95% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $124.37 | - | 1 | Feb 23, 2017 |
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $22.99
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $3.65
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.84
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.14
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $31.53
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $16.92
Upside: -
Teva Pharmaceutical
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $17.73
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $5.99
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $10.30
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $38.10
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.56
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.40
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $48
Current: $1.42
Upside: +3,280.28%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $285.42
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $4.55
Upside: +954.95%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $124.37
Upside: -